EUVIMEDEUVIMED entdecken
Crossref

Outcomes of Children With Orbital Rhabdomyosarcoma, 1991–2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT)

Jonathan Metts, James Anderson, Christian Vokuhl, Ewa Koscielniak, Cristian Urla, Rajkumar Venkatramani, John Breneman, Julie Bradley, Michael Arnold, Veronique Minard-Colin, Gianni Bisogno, Henry Mandeville und 5 weitere

Pediatric Blood & Cancer · 2026-10 · 73 (10)

DOI: 10.1002/1545-5017.70613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 08.08.2026. Verfasst von Jonathan Metts und 16 weiteren Autor:innen. Beteiligte Einrichtung: Sarcoma Department, Moffitt Cancer Center, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Orbital Neoplasms, Rhabdomyosarcoma, Neoplasm Recurrence, Local. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Cancer Research Foundation, Children's Research Foundation, Maddie's Promise.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with orbital rhabdomyosarcoma (ORMS) historically have 10‐year overall survival (OS) rates > 85% with multimodal therapy. We aimed to determine if favorable outcomes were preserved on contemporary international cooperative group trials in the context of shifting treatment approaches, including chemotherapy reduction and changes in the indications for radiation therapy (RT) and RT dose.

Methods

We identified patients with newly diagnosed ORMS (orbit and eyelid sites) from 11 North American and European cooperative group trials from 1991 to 2016. Demographic and clinical characteristics were collected. Event‐free survival (EFS) and OS were calculated from the time of trial enrollment except post‐relapse OS, which was calculated from the time of recurrence.

Results

Of 679 patients with ORMS, the 10‐year EFS and OS were 74.6% (71.0%–77.8%) and 92.9% (90.6%–94.8%). In patients with Group III, non‐alveolar ORMS ( n = 425, 62.6%), the 10‐year EFS and OS were 78% (74%–82%) and 95% (92%–97%), respectively. Anaplasia was associated with inferior 10‐year EFS (79.8% vs. 84.2%, p = 0.03), and the 10‐year post‐recurrence OS was 78% (67%–86%). Patients with localized alveolar ORMS ( n = 81; PAX::FOXO1 fusion positive in 13/33 patients with known fusion status) had a 10‐year EFS of 71% (60%–80%) and OS of 88% (79%–94%). Infants < 1 year ( n = 22) had a 5‐year EFS of 31% (12%–52%) and OS of 61% (37%–78%). Metastatic ORMS (age ≥1) was rare ( n = 5; 4/5 alveolar histology), and no patients survived more than 4 years.

Conclusion

Favorable survival in patients with ORMS was preserved despite shifts in treatment strategies. Patients with localized alveolar ARMS and recurrent ORMS had favorable survival. Infants < 1 year and those ≥ 1 with metastatic disease had poor prognosis and require new therapeutic approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orbital NeoplasmsRhabdomyosarcomaNeoplasm Recurrence, LocalHumansFemaleMaleChild, PreschoolInfantChildSurvival RateAdolescentPrognosisCombined Modality TherapyFollow-Up StudiesDisease-Free Survival

Stichwörter der Autor:innen

orbitrhabdomyosarcomasurvival

Autor:innen und Institutionen

  • Sarcoma Department, Moffitt Cancer Center, Tampa, Florida, USA.
  • Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida, USA.
  • University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Section of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn, Germany.
  • Klinik Für Kinder- und Jugendmedizin, Kinderheilkunde I - Allgemeine Pädiatrie, Hämatologie Und Onkologie, Universitätsklinikum Tübingen, Tübingen, Germany.
  • Department of Pediatric Surgery and Pediatric Urology, University Children's Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.

Förderung

  • Cancer Research Foundation
  • Children's Research Foundation
  • Maddie's Promise
  • Summer's Way Foundation
  • St. Baldrick's Foundation
  • Andrew McDonough B+ Foundation
  • Seattle Children's Foundation
  • Rally Foundation

Zitieren

APA

Metts, J., Anderson, J., Vokuhl, C., Koscielniak, E., Urla, C., Venkatramani, R., Breneman, J., Bradley, J., Arnold, M., Minard-Colin, V., Bisogno, G., Mandeville, H., Merks, J., Timmerman, B., von Kalle, T., Sparber-Sauer, M., & Walterhouse, D. (2026). Outcomes of Children With Orbital Rhabdomyosarcoma, 1991–2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatric Blood & Cancer, 73(10). https://doi.org/10.1002/1545-5017.70613

Vancouver

Metts J, Anderson J, Vokuhl C, Koscielniak E, Urla C, Venkatramani R, et al. Outcomes of Children With Orbital Rhabdomyosarcoma, 1991–2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatric Blood & Cancer. 2026;73(10). doi:10.1002/1545-5017.70613

BibTeX
@article{Metts2026,
  author = {Metts, Jonathan and Anderson, James and Vokuhl, Christian and Koscielniak, Ewa and Urla, Cristian and Venkatramani, Rajkumar and Breneman, John and Bradley, Julie and Arnold, Michael and Minard-Colin, Veronique and Bisogno, Gianni and Mandeville, Henry and Merks, Johannes and Timmerman, Beate and von Kalle, Thekla and Sparber-Sauer, Monika and Walterhouse, David},
  title = {Outcomes of Children With Orbital Rhabdomyosarcoma, 1991–2016: A Report From the International Soft Tissue Sarcoma Consortium (INSTRuCT)},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {10},
  doi = {10.1002/1545-5017.70613}
}
Kostenlos starten →